William Blair downgraded Dentsply Sirona from Outperform to Mkt Perform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/7/2025 | Outperform → Mkt Perform | William Blair | |
| 4/15/2025 | $14.00 | Overweight → Equal-Weight | Morgan Stanley |
| 3/13/2025 | Buy → Hold | Needham | |
| 2/14/2025 | $20.00 | Equal Weight | Wells Fargo |
| 1/23/2025 | $30.00 → $20.00 | Buy → Hold | Jefferies |
| 1/7/2025 | $20.00 | Outperform → In-line | Evercore ISI |
| 12/4/2024 | $21.00 | Neutral | Mizuho |
| 11/7/2024 | Outperform → Market Perform | Leerink Partners |
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4/A - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
William Blair downgraded Dentsply Sirona from Outperform to Mkt Perform
Morgan Stanley downgraded Dentsply Sirona from Overweight to Equal-Weight and set a new price target of $14.00
Needham downgraded Dentsply Sirona from Buy to Hold
8-K/A - DENTSPLY SIRONA Inc. (0000818479) (Filer)
10-Q - DENTSPLY SIRONA Inc. (0000818479) (Filer)
8-K - DENTSPLY SIRONA Inc. (0000818479) (Filer)
Dentsply Sirona Reports Third Quarter 2025 Results Net sales of $904 million decreased (5.0%) as-reported, decreased (8.0%) in constant currency including (5.5%) driven by Q3 2024 Byte impact and ERP pre-buyGAAP gross margin of 48.8%, GAAP net loss per share of ($2.14)Adjusted gross margin of 52.6%, adjusted EBITDA margin of 18.4%, adjusted EPS of $0.37Revised FY25 outlook Executing its Return-to-Growth action plan to drive improved performance and deliver sustained, profitable growthProvides leadership updates to support transformation strategy CHARLOTTE, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced its f
CHARLOTTE, N.C., Oct. 08, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company will host an investor conference call and live webcast on Thursday, November 6, 2025, at 8:30 am ET to review its financial results for the third quarter of fiscal year 2025. The Company will issue a press release and provide a presentation with summary financial information, which will be made available on the Investors section of the Company's website at https://investor.dentsplysirona.com prior to the call. Conference Call / Webcast Information The live webcast will be available on the Investors section of the Company's website at
CHARLOTTE, N.C., Oct. 02, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Aldo M. Denti has been appointed Executive Vice President and Chief Commercial Officer (CCO), effective October 6, 2025. The appointment is designed to sharpen the Company's focus on the customer by aligning its Global Business Units and Commercial Organizations more closely - streamlining how Dentsply Sirona works and delivers. Mr. Denti is a global business leader with over 25 years of experience driving transformative growth in the Medical Device and Consumer Health sectors. His expertise spans sales, marketing, strategic planning, and successf
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)
SC 13G/A - DENTSPLY SIRONA Inc. (0000818479) (Subject)
SC 13G - DENTSPLY SIRONA Inc. (0000818479) (Subject)
SC 13G - DENTSPLY SIRONA Inc. (0000818479) (Subject)
Dentsply Sirona Reports Third Quarter 2025 Results Net sales of $904 million decreased (5.0%) as-reported, decreased (8.0%) in constant currency including (5.5%) driven by Q3 2024 Byte impact and ERP pre-buyGAAP gross margin of 48.8%, GAAP net loss per share of ($2.14)Adjusted gross margin of 52.6%, adjusted EBITDA margin of 18.4%, adjusted EPS of $0.37Revised FY25 outlook Executing its Return-to-Growth action plan to drive improved performance and deliver sustained, profitable growthProvides leadership updates to support transformation strategy CHARLOTTE, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced its f
CHARLOTTE, N.C., Oct. 08, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company will host an investor conference call and live webcast on Thursday, November 6, 2025, at 8:30 am ET to review its financial results for the third quarter of fiscal year 2025. The Company will issue a press release and provide a presentation with summary financial information, which will be made available on the Investors section of the Company's website at https://investor.dentsplysirona.com prior to the call. Conference Call / Webcast Information The live webcast will be available on the Investors section of the Company's website at
CHARLOTTE, N.C., July 21, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or "the Company") (NASDAQ:XRAY) today announced that Daniel Scavilla, an established business leader with more than three decades of experience in the medical technology and pharmaceutical industries and a current member of the Board of Directors of Dentsply Sirona (the "Board"), has been appointed President and Chief Executive Officer, effective August 1, 2025. He succeeds Simon Campion, who is leaving the Company on July 31, 2025. Mr. Scavilla recently served as President and Chief Executive Officer of Globus Medical, where he led the acquisition of NuVasive and oversaw the integration of the two
CHARLOTTE, N.C., Oct. 02, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Aldo M. Denti has been appointed Executive Vice President and Chief Commercial Officer (CCO), effective October 6, 2025. The appointment is designed to sharpen the Company's focus on the customer by aligning its Global Business Units and Commercial Organizations more closely - streamlining how Dentsply Sirona works and delivers. Mr. Denti is a global business leader with over 25 years of experience driving transformative growth in the Medical Device and Consumer Health sectors. His expertise spans sales, marketing, strategic planning, and successf
CHARLOTTE, N.C., May 29, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Matthew E. Garth has been appointed Executive Vice President and Chief Financial Officer, effective May 30, 2025. Mr. Garth brings nearly 30 years of proven financial management expertise to Dentsply Sirona, with a focus on driving value creation. He most recently served as Chief Financial Officer & Chief Administrative Officer of The Scotts Miracle-Gro Company, a global leader of branded consumer lawn and garden products. Prior to ScottsMiracle-Gro, Mr. Garth held numerous financial leadership roles at large, multinational companies, including Min
CHARLOTTE, N.C., March 17, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (XRAY) today announced that David Ferguson has been appointed Senior Vice President, Global Business Unit Leader, effective March 14, 2025. In this role he will lead the global business unit teams managing the dental product portfolio, serve as a member of the Executive Management Team and report directly to Chief Executive Officer, Simon Campion. David Ferguson joins Dentsply Sirona with 25 years of experience in MedTech and healthcare with a proven track record of delivering results, competing in a global marketplace and leading global product strategy. Mr. Ferguson has se